Catalogo dei Corsi di studio

APRILE 2020
FRANCESCA ROMANA MAURO

Settore scientifico disciplinare MED 15
Ateneo Università degli Studi di ROMA Sapienza
Struttura di afferenza Dipartimento. di Medicina Translazionle e di Precisione
Divisione di Ematologia

Recapiti Tel: +39 06 499741-426-777
E-mail: francescaromana.mauro@uniroma1.it
mauro@bce.uniroma1.it

ISTRUZIONE E FORMAZIONE
1980 Laurea in Medicina e Chirurgia (110/110 e lode),
Università Sapienza, Roma.
1982 Stage presso Hôpital Sant-Louis, Parigi,
Unité Functionelle de Greffe de Moelle Osseuse, (Prof. E. Glukman)
1983 Specializzazione in Ematologia Clinica e di Laboratorio (70/70 e lode)
Università Sapienza, Roma.
1986 Stage presso Hammersmith Hospital, Londra,
Bone Marrow Transplantation Unit, (Prof. J. Goldman)
1989 Dottorato di Ricerca in Ematologia,
Università degli Studi di Ancona.
2012 Formazione manageriale per medici specialisti in Oncoematologia
SDA-Università Bocconi, Milano.

CARRIERA E TITOLI
2020 Professore Associato
Sezione di Ematologia, Dipartimento. di Medicina Translazionle e di Precisione
2017 Incarico professionale FAS, per il management di pazienti affetti da malattie linfoproliferative croniche- Azienda Policlinico Umberto I, Roma
2015 Abilitazione Nazionale a Professore di II fascia- Settore concorsuale 06/D3
Malattie del sangue, oncologia e reumatologia in corso di validità ai sensi dell art. 16 della Legge n. 240/2010.
2006 Professore aggregato/ricercatore in Ematologia presso il Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza - Università di Roma
2002-2006 Ricercatore Universitario Confermato presso il Dipartimento di Biotecnologie
Cellulari ed Ematologia, Sapienza - Università di Roma
1991 Dirigente Medico di primo livello presso la UOC Ematologia, Dipartimento Assistenziale Integrato di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Roma.
1990 Funzionario Tecnico Laureato presso il Dipartimento Biotecnologie Cellulari ed
Ematologia, - Università Sapienza di Roma-
1986-1989 Dottorato in Ematologia
Università di Ancona-Università Sapienza, Roma
1983-1986 Specialista in ematologia, frequentatore, Istituto di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università Sapienza, Roma
1980-1983 Specializzazione in Ematologia
Istituto di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia,
Università Sapienza, Roma

SINTESI DELLE PRINCIPALI ATTIVITA
Parole chiave: Leucemia Linfatica cronica (LLC); Anemia Emolitica Autoimmune (AEA); diagnosi, prognosi, terapia.
Attività assistenziale: Referente della gestione clinica e terapeutica di pazienti affetti da malattie linfoproliferative croniche, leucemia linfatica cronica e da anemia emolitica autoimmune.
Attività Didattica
Titolare dell insegnamento Malattie del Sangue" presso l Università Sapienza di Roma, Corso di Laurea Magistrale in Medicina e Chirurgia D e Scienze Infermieristiche A e H . Docente presso la Scuola di Specializzazione in Ematologia.
Attività di Ricerca
Disegno, coordinazione, partecipazione a progetti di ricerca di tipo innovativo, multicentrici per la valutazione dell efficacia di nuovi approcci terapeutici nella LLC.

ATTIVITA DIDATTICA E CORRELATA ALLA DIDATTICA- UNIVERSITA DI ROMA SAPIENZA
2012 - tuttora
Titolare insegnamento Malattie del Sangue - Corso di Laurea Magistrale in Medicina e Chirurgia "D" presso la Facoltà di Medicina e Odontoiatria, Università di Roma, Sapienza
2012- tuttora
Coordinatore del corso integrato di Patologia integrata IV del Corso di Laurea Magistrale in Medicina e Chirurgia "D" presso la Facoltà di Medicina e Odontoiatria, Università di Roma, Sapienza
2016- tuttora Delegato dal Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia "D" presso la Facoltà di Medicina e Odontoiatria, Università Sapienza, Roma. nell ambit della:
1) Commissione Tecnica di ProgrammazioneDidattico Pedagogica (CTP)
2) Rapporti internazionali (Erasmus, Internship)
3) E-learning e sviluppo di attività di ricerca in rapporto con la Conferenza Permanente dei Presidenti di CLM in Medicina e Chirurgia
2013- tuttora Titolare insegnamento Malattie del Sangue del Corso di Laurea in Infermieristica, Università di Roma Sapienza di Roma, sede di Colleferro.
2015- tuttora Titolare insegnamento Malattie del Sangue del Corso di Laurea in Infermieristica A, dell'Università di Roma Sapienza , Policlinico Umberto I.
2000 - 2012
Docente della II Scuola di Specializzazione in Ematologia, Università Sapienza di Roma (Direttore Prof. G. Girelli).
2006 - tuttora
Docente della I Scuola di Specializzazione in Ematologia dell'Università di Roma Sapienza (Direttore, Prof. Mandelli, successivamente, Prof. R. Foà)
1999-2013
Docente del Dottorato in Scienze Ematologiche dell'Università di Roma Sapienza (Coordinatori, Prof Mandelli e successivamente, Prof. R. Foà)
2011 - 2012
Docente del Dottorato in Scienze Immunologiche, Ematologiche e Reumatologiche dell'Università "Sapienza" di Roma (Coordinatore prof. A Santoni)
2011- 2013
Docente del Corso di Laurea in Fisioterapia "H", dell'Università di Roma Sapienza sede di Bracciano.

ATTIVITA DIDATTICA- ALTRE UNIVERSITA
2003-2016 Docente presso il corso Stages in Ematologia organizzato dall istituto di Ematologia dell Università di Bologna- Istituto di Ematologia L. e A. Seràgnoli .
2013- 2017 Docente presso Master Universitario Interateneo di II livello Diagnosi e terapia dei pazienti con linfoma organizzato dall Istituto di Ematologia dell Università degli Studi di Udine.
2004-2009 Docente presso la Mediterranean School of Oncology ' Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO).

CAPACITA E COMPETENZE RELAZIONALI
Convegni: relazioni ed organizzazione
Ha patecipato negli ultimi 10 anni a più di 100 convegni educazionali promossi da Società Scientifiche (SIE-SIES-GIMEMA) Università, Aziende Ospedaliere, eventi ECM ed organizzato eventi scientifici a carattere educazionale.

Appartenenza a Societa Scientifiche Partecipazione a boards
1. Segretario del Working Party Malattie Linfoproliferative Croniche del GIMEMA (Gruppo Italiano Malattie EMatologiche dell Adulto) dall anno 2002-2018.
2. Membro della Consensus Conference SIE-SIES-GITMO per la elaborazione delle linee guida per il trattamento della Leucemia Linfatica Cronica (2006-2014).
3. Membro della Società Italiana di Ematologia (SIE).
4. Membro dell European Research Initiative on CLL (ERIC).
5. Membro e coordinatore nell ambito dell iniziativa di studio italiana Campus .
6. Partecipazione a boards scientifici organizzati da società scientifiche ed aziende

Attività di Referee
Referee per le seguenti riviste internazionali peer-reviewed: Blood, Lancet Oncology, Lancet Haematology, Haematologica, American Journal of Hematology, European Journal of Hematology, Oncotarget, Leukemia, Cancers.

PROGETTI DI RICERCA
Coinvolta negli ultimi 10 anni in 28 progetti di ricerca di cui 15 come partecipante e 13 come responsabile coordinatore.

PUBBLICAZIONI SCIENTIFICHE
Autore e coautore di più di 150 pubblicazioni scientifiche su riviste internazionali peer reviewed e di contributi a capitoli di testi scientifici in Ematologia.
Impact factor totale (IF): >750.455 (IF per anno di pubblicazione; fonte: Web of Science)

REFERENZE- impact factor

158 Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Recchia AG, Varettoni M, Murru R, Chiarenza A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Fraticelli V, Vigna E, Botta C, Tripepi G, Arrigo G, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Rigolin GM, Rossi D, Di Raimondo F, Gaidano G, Polliack A, Cuneo A, Foà R, Gattei V. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2020 Apr 14. doi: 10.1038/s41375-020-0833-x. [Epub ahead of print] 9.944
157 Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. Blood. 2020 Apr 8. pii: blood.2019003453. doi: 10.1182/blood.2019003453. [Epub ahead of print] 16.562
156 Herishanu Y, Shaulov A, Fineman R, Ba i -Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol. 2020 Feb 25. doi: 10.1002/ajh.25766. [Epub ahead of print] 5.303
155 Raponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A, Arena V, Mariglia P, Mauro FR, Gentile M, Cutrona G, Moia R, Favini C, Morabito F, Rossi D, Gaidano G, Guarini A, Del Giudice I, Foà R. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. Br J Haematol. 2020 Feb 16. doi: 10.1111/bjh.16434. [Epub ahead of print] 5.206
154 Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F,Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G, Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice I, Della Starza I, De Propris MS, Raponi S, Guarini AR, Foà R. High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica. 2020 Jan 30. pii:
haematol.2019.235705. doi: 10.3324/haematol.2019.235705. [Epub ahead of print] PubMed PMID: 32001537. 7.57
153 Prezzo A, Cavaliere FM, Bilotta C, Pentimalli TM, Iacobini M, Cesini L, Foà R, Mauro FR, Quinti I. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Leuk Res. 2019;87:106233. doi: 10.1016/j.leukres.2019.106233. Epub 2019 Oct 3. PubMed PMID: 31639635. 2.066
152 Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R,Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print] 7.57
151 Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR,Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S,Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centr Italian experience.
Br J Haematol. 2019 Jul 31. doi:10.1111/bjh.16123; [Epub ahead of print] 5.206
150 Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L. A SCORING SYSTEM TO PREDICT THE RISK OF ATRIALFIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2655. [Epub ahead of print] 3.439
149 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M. HIF-1 is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.
Haematologica. 2019; pii: haematol.2019.217430.10.3324/haematol.2019.217430. [Epub ahead of print]. 7.57
148 Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C,
Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance inTreatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy12.
Cancers 2019; 26;11(7): E896 doi: 10.3390/cancers11070896. 6.162
147 Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
Br J Cancer. 2019;121(2):150-156. 5.416
146 Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L,Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D,Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients withrelapsed/refractory chronic lymphocytic leukemia.
Haematologica. 2019 May 16.pii: haematol.2018.205930. doi: 10.3324/haematol.2018.205930. [Epub ahead of print]. 7.57
145 Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, Barbieri M, Silvestris I, Fabris S, Morabito F, Neri A, Barcellini W, Cortelezzi A. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
Leukemia. 2019;33(6):1519-1522. 9.944
144 Guarini A, Peragine N, Messina M, Marinelli M, Ilari C, Cafforio L, Raponi S, Bonina S, Mariglia P, Mauro FR, Gaidano G, Del Giudice I, Foà R. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Br J Haematol. 2019 Feb;184(3):392-396.
5.206
143 Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R. Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
Br J Haematol. 2019 ;185(1):156-159.
5.206
142 Mauro FR, Caputo MD, Rosati S, Pepe S, De Benedittis D, De Luca ML, Foà R. Balancing efficacy and toxicity of targeted agents currently used for the
treatment of patients with chronic lymphocytic leukemia.
Expert Rev Hematol. 2018;11(8):601-611. 2.505
141 Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.
Am J Hematol. 2018 ;93(9):216-219. 6.137
140 Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.
Eur J Haematol. 2018 Jul 24. doi:10.1111/ejh.13149. [Epub ahead of print] PubMed PMID: 30039576.
2.217
139 Rossi, D. Gramegna, F. Paoloni, B. Fattizzo, F. Binda, M. D Adda, M. Farina, E. Lucchini, F R. Mauro, F. Salvi, M. Marchetti, P. Fazi, F. Zaja, W. Barcellini Short course of bortezomid in anemic patients with relapsed cold agglutinin disease. A phase II prospective study by the GIMEMA study group.
Blood. 2018;132(5):547-550. 16.562
138 Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B,Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
Br J Haematol. 2018;181(2):229-233. 5.128
137 Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica. 2018l;103(7):1209-1217. 7.57
136 Mauro FR, Foà R. Gene mutations in lenalidomide-treated CLL.
Blood. 2018 19;131(16):1769-1771. 16.562
135 Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A,Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A,Morabito F. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Leukemia. 2018 ;32(8):1869-1873. 9.944
134 Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP,Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Hematol Oncol. 2018;36(4):624-63. 3.439
133 Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.
Ann Oncol. 2018;29(4):966-972. 14.196
132 Mauro FR, Foà R. Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
Lancet Oncol. 2018 ;19(1):7-8. 35.386
131 Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, BossioS, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
Am J Hematol. 2018;93(2):35-37. 6.137
130 Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.
Leukemia.2018;32(2):543-546. 9.944
129 Mauro FR, Trastulli F, Alessandri C, Valesini G, Giovannetti G, Riemma C, Porrazzo M, Pepe S, Colafigli G, Caputo MD, De Propris MS, Guarini AR, Girelli G, Coluzzi S, Foà R. Clinical relevance of silent red blood cell autoantibodies.
Haematologica. 2017;102(12):473-475. 9.090
128 Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R. Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.
Haematologica. 2017;102(9):352-355. 9.090
127 Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Am J Hematol. 2017;92(6):529-535. 5.303
126 Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M. Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leuk Res. 2017; 27;7:65-71. 2.319
125 Mauro FR. Another treatment option for relapsed or refractory chronic lymphocytic leukaemia.
Lancet Oncol. 2017;18(3):270-271. Epub 2017 Jan 28. 36.418
124 Mauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, De Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Leuk Lymphoma. 2017 ;58(7):1640-1647 2.644
123 Vigna E, Martino B, Bacci F, Recchia AG, Mendicino F, Morelli R, Mauro FR, Musolino C, Greco R, Lucia E, Sabattini E, Morabito F, Gentile M. Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
Chemotherapy. 2017;62(6):350-352. 2.000
122 Mauro FR, Salaroli A, Caputo MD, Colafigli G, Petrucci L, Campanelli M, Ferretti A, Guarini AR, Foà R. Management of elderly chronic lymphocytic leukemia.
Expert Rev Hematol. 2016;9(12):1165-1175. 2.246
121 Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.
Blood. 2016;128(16):2093-2095. 13.164
120 Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
Eur J Cancer. 2016; 60:154-65. 6.029
119 Mauro FR, Coluzzi S, Paoloni F, Trastulli F, Armiento D, Ferretti A, Giovannetti G, Colafigli G, Molica M, la Rocca U, De Propris MS, Caronna R, Morano G, Guarini A, Girelli G, Foà R. Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up.
Am J Hematol. 2016;91(7):319-200. 5.275
118 Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
Leuk Lymphoma. 2016;57(10):2429-2431 2.755
117 Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.
Leukemia. 2016. 30(6):1440-1443. 11.702
116 Del Giudice I, Marinelli M, Wang J, Bonina S, Messina M, Chiaretti S, Ilari C, Cafforio L, Raponi S, Mauro FR, Di Maio V, De Propris MS, Nanni M, Ciardullo C, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
Br J Haematol. 2016;172(3):371-383. 5.670
115 Cavalli M, Ilari C, Del Giudice I, Marinelli M, Della Starza I, De Propris MS, De Novi LA, Nunes V, Cafforio L, Raponi S, Mancini F, Mauro FR, Tiacci E, Falini B, Guarini A, Foà R. A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin.
Br J Haematol. 2016 ;174(2):329-31. 5.670
114 Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Lionetti M, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Musto P, Federico M, Neri A, Ferrarini M, Morabito F. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Eur J Haematol. 2016;96(1):36-45. 2.653
113 Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzoni V, Cervetti G, Pitini V, Foà R, Sica S, D'Arena G. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Leuk Res. 2015;39(10):1066-70. 2.606
112 Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Blood. 2015;126(16):1921-1924. 11.847
111 Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.
Leukemia.2015;29(6):1360-5. doi: 10.1038/leu.2015.21 12.104
110 Tavolaro S, Colombo T, Chiaretti S, Peragine N, Fulci V, Ricciardi MR, Messina M, Bonina S, Brugnoletti F, Marinelli M, Di Maio V, Mauro FR, Del Giudice I, Macino G, Foà R, Guarini A. Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.
Genes Chromosomes Cancer. 2015;54(4):222-34. 3.960
109 Chiaretti S, Marinelli M, Del Giudice I, Bonina S, Piciocchi A, Messina M, Vignetti M, Rossi D, Di Maio V, Mauro FR, Guarini A, Gaidano G, Foà R. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Leuk Lymphoma. 2014;55(12):2785-2792. 2.891
108 Cuneo A, Marchetti M, Barosi G, Billio A, Brugiatelli M, Ciolli S, Laurenti L, Mauro FR, Molica S, Montillo M, Zinzani P, Tura S. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
Leuk Res. 2014 ;38(11):1269-1277. 2.351
107 Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG, De Stefano L, Campanelli M, Giannarelli D, Bossio S, Morabito L, Vigna E, Gaidano G, Foà R, Morabito F. Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
Br J Haematol. 2014 Oct;167(2):224-232. 4.971
106 Raponi S, Della Starza I, De Propris MS, Del Giudice I, Mauro FR, Marinelli M, Di Maio V, Piciocchi A, Foà R, Guarini A. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Br J Haematol. 2014 Aug ;166(3):360-368. 4.971
105 Messina M, Del Giudice I, Khiabanian H, Rossi D, Chiaretti S, Rasi S, Spina V, Holmes AB, Marinelli M, Fabbri G, Piciocchi A, Mauro FR, Guarini A, Gaidano G, Dalla-Favera R, Pasqualucci L, Rabadan R, Foà R. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
Blood. 2014 10;123(15):2378-88. 10.452
104 Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
Am J Hematol. 2014;89(5):480-6. 3.798
103 Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell Adulto Working Party for Chronic ymphoproliferative Disorders. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Leuk Res. 2014;38(2):198-203. 2.351
102 Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
Leukemia. 2014;28(3):642-8. 10.431
101 Del Giudice I, Chiaretti S, Santangelo S, Tavolaro S, Peragine N, Marinelli M, Ilari C, Raponi S, Messina M, Nanni M, Mauro FR, Piciocchi A, Bontempi K, Rossi D, Gaidano G, Guarini A, Foà R. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
Am J Hematol. 2014;89(1):74-82. 3.79
100 Gentile M, Cutrona G, Fabris S, Pesce EA, Baldini L, Di Raimondo F, Musolino C, Di Tonno P, Di Renzo N, Molica S, Brugiatelli M, Ilariucci F, Zupo S, Matis S,Maura F, Vigna E, Angrilli F, Recchia AG, Quarta G, Iannitto E, Fragasso A, Musto P, Spriano M, Vincelli I, Vallisa D, Cortelezzi A, Mauro FR, Foà R, Federico M, Neri A, Ferrarini M, Morabito F. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Am J Hematol. 2013 ;88(7):539-544. 3.477
99 Tavolaro S, Peragine N, Chiaretti S, Ricciardi MR, Raponi S, Messina M, Santangelo S, Marinelli M, Di Maio V, Mauro FR, Del Giudice I, Foà R, Guarini A. IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells.
Leuk Res. 2013;37(4):455-462. 2.692
98 Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, Tuana G, Lionetti M, Guercini N, Novella E, Nichele I, Montaldi A, Autore F, Gregorini A, Barcellini W, Callea V, Mauro FR, Laurenti L, Foà R, Neri A, Rodeghiero F, Cortelezzi A. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.
Am J Hematol. 2013 ;88(1):32-36. 3.477
97 Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceri G, Barbieri Maura F, Matis S, Colombo M, Gentile M, Recchia AG, Anna Pesce E, Di Raimondo F Musolino C, Gobbi M, Di Renzo N, Mauro FR, Brugiatelli M, Ilariucci F, Lipari MG, Angrilli F, Consoli U, Fragasso A, Molica S, Festini G, Vincelli I, Cortelezzi A,Federico M, Morabito F, Ferrarini M, Neri A. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
Am J Hematol. 2013;88(1):24-31. 3.477
96 Marinelli M, Peragine N, Di Maio V, Chiaretti S, De Propris MS, Raponi S,Tavolaro S, Mauro FR, Del Giudice I, Guarini A, Foà R. Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.
Haematologica. 2013 ;98(3):371-375. 5.868
95 CLL Trialists Collaborative Group(1).Collaborators: Bauduer M, Gribben J, Herrmann R, Thiel E, Rai K, Larson R,Ferrara F, Barnard J, Pearce H, Taylor C, Brillant C, Steurer M, Weingart O, Flinn IW, Funkhouser A, Tallman M, Sun Z, Jaksic B, Suciu S, Chevret S, Dighiero G, Leporrier M, Frankel SR, Sirard C, Hillmen P, Trehu B, Felder M, Busch R,Eichhorst B, Hallek M, Stilgenbauer S, Pangalis G, Bezares R, van Oers MH, van Putten W, Gobbi M, Spriano M, Mabed M, Catovsky D, Richards S, Wade R, Abdelhamid T, Dearden C, Knauf W, Blonski J, Jamroziak K, Robak T, Mauro F, Hiddeman W, Johnson SA, Longthorne G, Juliusson G, Pulluqi P, Zinzani PL, Pozzato G, Oncology US, Reynolds C, Furman RR, Durrant J, Elphinstone P, Evans V, Gettins L, Hicks C, James S, Clarke M, MacKinnon L, McHugh TM, Morris P, Read S, Gregory C.Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials.
Haematologica. 2012 Mar;97(3):428-436. 5.935

94 Molica S, Mauro FR, Molica M, Del Giudice I, Foà R. Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.
Leuk Lymphoma. 2012 ;53(9):1660-1665. 2.301
93 Molica S, Gentile M, Mauro FR, Brugiatelli M, Federico M, Sperduti I, Neri A, Ferrarini M, Foà R, Morabito F. An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0.
Acta Haematol. 2012;127(3):149-151. 0.894
92 Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L, Zallio F, Callea V, Maura F, Martinelli S, Piciocchi A, Reda G, Foà R; GIMEMA Chronic Lymphoproliferative Disorders Working Party. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
BrJ Haematol. 2012;156(4):481-489. 4.942
91 Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, Martelli M, Di Rocco A, Finolezzi E, Paoloni F, Mauro FR, Cuneo A, Guarini A, Foà R. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes.
Br J Haematol. 2012 ;156(5):601-611. 4.942
90 Bacalini MG, Tavolaro S, Peragine N, Marinelli M, Santangelo S, Del Giudice I, Mauro FR, Di Maio V, Ricciardi MR, Caiafa P, Chiaretti S, Foà R, Guarini A, Reale A. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
Exp Hematol. 2012;40(3):197-206.e1. 2.905
89 Guarini A, Marinelli M, Tavolaro S, Bellacchio E, Magliozzi M, Chiaretti S, De Propris MS, Peragine N, Santangelo S, Paoloni F, Nanni M, Del Giudice I, Mauro FR, Torrente I, Foà R. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
Haematologica. 2012;97(1):47-55. 5.935
88 Mauro FR, Bandini G, Barosi G, Billio A, Brugiatelli M, Cuneo A, Lauria F, Liso V, Marchetti M, Meloni G, Montillo M, Zinzani P, Tura S; Italian Society of Hematology; Società Italiana di Ematologia Sperimentale; Gruppo Italiano Trapianto di Midollo Osseo. SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
Leuk Res. 2012 ;36(4):459-466. 2.764
87 Capobianchi A, Iori AP, Mauro FR, Torelli GF, Micozzi A, Girmenia C, Foà R, Gentile G. Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient.
J Clin Virol. 2011;52(3):247-250. 3.969
86 Molica S, Mirabelli R, Molica M, Levato L, Mauro FR, Foà R. Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.
Cancer Manag Res. 2011;3:211-217. -
85 Del Giudice I, Mauro FR, Foà R. Chronic lymphocytic leukemia in less fit patients: "slow-go".
Leuk Lymphoma. 2011;52(12):2207-2216. 2.580
84 Breccia M, Salaroli A, Loglisci G, Martelli M, D'Elia GM, Nanni M, Mauro FR, Alimena G. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Leuk Res. 2011;35(10):1409-1411. 2.923
83 Girmenia C, Santilli S, Ballarò D, Del Giudice I, Armiento D, Mauro FR. Enteral nutrition may cause false-positive results of Aspergillus galactomannan assay in absence of gastrointestinal diseases.
Mycoses. 2011;54(6):883-884. 2.247
82 Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, Tedeschi A, Ambrosetti A, Gaidano G, Leone G, Foà R. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Am J Hematol. 2011;86(12):1007-1012. 4.671
81 Chiaretti S, Tavolaro S, Marinelli M, Messina M, Del Giudice I, Mauro FR, Santangelo S, Piciocchi A, Peragine N, Truong S, Patten N, Ghia EM, Torrente I, De Propris MS, Nanni M, Lawrence J, Guarini A, Foà R. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Genes Chromosomes Cancer. 2011;50(4):263-274. 3.306
80 Del Giudice I, Mauro FR, De Propris MS, Santangelo S, Marinelli M, Peragine N, Di Maio V, Nanni M, Barzotti R, Mancini F, Armiento D, Paoloni F, Guarini A, Foà R. White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.
Haematologica. 2011 ;96(4):626-630. 6.424
79 Marinelli M, Raponi S, Del Giudice I, De Propris MS, Nanni M, Intoppa S, Milani ML, Mauro FR, Guarini A, Foà R. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
Am J Clin Pathol. 2011;135(1):173-174. 2.598
78 Molica S, Mauro FR, Giannarelli D, Lauria F, Cortelezzi A, Brugiatelli M, Liso V, Cuneo A, Foà R. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.
Haematologica. 2011 ;96(2):277-283. 6.424
77 Molica S, Di Raimondo F, Cutrona G, Fabris S, Mauro F, Brugiatelli M, Baldini L, Musto P, Sacchi S, Cortelezzi A, Foà R, Neri A, Federico M, Ferrarini M, Morabito F; Gruppo Italiano Studio Linfomi (GISL). Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio
Linfomi (GISL) experience.
Leuk Res. 2010;34(8):217-218. 2.555
76 Tavolaro S, Chiaretti S, Messina M, Peragine N, Del Giudice I, Marinelli M, Santangelo S, Mauro FR, Guarini A, Foà R. Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.
Leuk Res. 2010;34(6):733-741. 2.555
75 Molica S, Mauro FR, Callea V, Giannarelli D, Lauria F, Rotoli B, Cortelezzi A, Liso V, Foà R. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.
Haematologica. 2010;95(3):464-469. 6.532
74 Del Giudice I, Mauro FR, De Propris MS, Starza ID, Armiento D, Iori AP, Torelli GF, Guarini A, Foà R. Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients.
Blood. 2009 24;114(13):2848-9. 10.555
73 Molica S, Digiesi G, Mauro F, Mirabelli R, Cutrona G, Vitelli G, Morabito F, Iuliano F, Foà R, Ferrarini M. Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Leuk Res. 2009 ;33(1):162-165. 2.358
72 Del Giudice I, Chiaretti S, Tavolaro S, De Propris MS, Maggio R, Mancini F, Peragine N, Santangelo S, Marinelli M, Mauro FR, Guarini A, Foà R. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases.
Blood. 2009 ;114(3):638-646. 10.555
71 Del Giudice I, Pileri SA, Rossi M, Sabattini E, Campidelli C, Starza ID, De Propris MS, Mancini F, Perrone MP, Gesuiti P, Armiento D, Quattrocchi L, Tafuri A, Amendola A, Mauro FR, Guarini A, Foà R. Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly.
Br J Haematol. 2009;144(5):726-731. 4.597
70 Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, Ricciardi MR, Santangelo S, Marinelli M, De Propris MS, Messina M, Mauro FR, Del Giudice I, Foà R. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.
Blood. 2008;112(3):782-792. 10.432
69 Crowther-Swanepoel D, Wild R, Sellick G, Dyer MJ, Mauro FR, Cuthbert RJ, Jonsson V, Matutes E, Dearden C, Wiley J, Fuller S, Catovsky D, Houlston RS. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL.
Blood. 2008 ;111(12):5691-3. 10.432
68 Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.
Blood. 2007 ;110(9):3326-3333. 10.896
67 Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, Maggio R, Peragine N, Santangelo S, Mauro FR, Landgraf P, Tuschl T, Weir DB, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Guarini A, Foà R, Macino G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.
Blood. 2007;1;109(11):4944-4951. 10.896
66 Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, Cortelezzi A, Laurenti L, Pogliani EM, Pedotti P, Liso V, Girelli G, Mandelli F, Zanella A; GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia.
Haematologica. 2006;91(12):1689-1692. 5.032
65 Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, Mauro FR, Meloni G, Zinzani PL, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica. 2006;91(12):1662-1673. 5.032
64 Mauro FR, Giammartini E, Gentile M, Sperduti I, Valle V, Pizzuti A, Guarini A, Giannarelli D, Foà R. Clinical features and outcome of familial chronic lymphocytic leukemia.
Haematologica. 2006;91(8):1117-1120. 5.032
63 Bottoni U, Mauro FR, Cozzani E, Innocenzi D, Del Giudice M, Parodi A, Rebora A, Mandelli F, Calvieri S. Bullous lesions in chronic lymphocytic leukaemia: pemphigoid or insect bites?
Acta Derm Venereol. 2006;86(1):74-6. ---
62 Gentile M, Mauro FR, Guarini A, Foà R. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia.
Curr Opin Oncol. 2005 ;17(6):597-604. 3.257
61 Gentile M, Mauro FR, Calabrese E, De Propris MS, Giammartini E, Mancini F, Milani ML, Guarini A, Foà R. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience.
Br J Haematol. 2005;130(4):549-557. 4.080
60 Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJ, Jonsson V, Langerak AW, Mauro FR, Fuller S, Wiley J, Lyttelton M, Callea V, Yuille M, Catovsky D, Houlston RS. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci.
Am J Hum Genet. 2005;77(3):420-429. 12.649
59 Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, Lauria F, Rotoli B, Montanaro M, Cortelezzi A, Liso V, Mandelli F, Foa R; GIMEMA CLL Study Group. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.
Leuk Lymphoma. 2005;46(4):553-560. 1.295
58 Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphismin ARLTS1.
N Engl J Med. 2005, 21;352(16):1667-1676. 44.016
57 Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E, Cerri M, LoganJ, Foà R, Gaidano G. Evidence of biased immunoglobulin variable gene usage in highlystable B-cell chronic lymphocytic leukemia.
Leukemia. 2004;18(12):1941-1947. 5.810
56 Orsini E, Pasquale A, Maggio R, Calabrese E, Mauro FR, Giammartini E, Guarini A, Foa R. Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro.
Br J Haematol. 2004;125(6):720-728. 3.195
55 Mauro FR, Zinzani P, Zaja F, Gentile M, Vegna ML, Stefoni V, Marin L, Fanin R, Baccarani M, Tura S, Mandelli F. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Haematologica. 2003;88(12):1348-1357. 3.453
54 Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response.
Cancer Res. 2003 ;63(15):4497-4506. 8.649
53 Mauro FR, Gentile M, Foa R. Erythropoietin and chronic lymphocytic leukemia.
Rev Clin Exp Hematol. 2002; Suppl 1:21-31. --
52 Bottoni U, Mauro FR, Innocenzi D, Del Giudice M, Devirgiliis, Panasiti V, Mancini M, Mastrecchia B, Calvieri S. Skin carcinomas in patients with chronic lymphocytic leukaemia.
Dermatologia Clinica 2003; 23 (2): 71-74. ---
51 Guarini A, Gaidano G, Mauro FR, Capello D, Mancini F, De Propris MS, Mancini M, Orsini E, Gentile M, Breccia M, Cuneo A, Castoldi G, Foa R. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features.
Blood. 2003;102(3):1035-1041. 10.120
50 Theodorou I, Abel L, Mauro F, Duprey B, Magnac C, Payelle-Brogard B, Davi F, Dighiero G. High occurence of DRB1 11 in chronic lymphocytic leukaemia families.
Br J Haematol. 2002;119(3):713-715. 3.052
49 Mauro FR, Foa R, Meloni G, Gentile M, Giammartini E, Giannarelli D, De Propris MS, Rapanotti MC, de Fabritiis P, Mandelli F. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Haematologica. 2002;87(9):926-933 3.226
48 Mauro FR, Gentile M, Mancini F, Giannarelli D, Guarini A, De Propriis MS, Cerretti R, Foa R. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Haematologica. 2002;87(6):602-608. 3.226
47 Ricciardi MR, Petrucci MT, Gregorj C, Ariola C, Lemoli RM, Fogli M, Mauro FR, Cerretti R, Foà R, Mandelli F, Tafuri A. Reduced susceptibility to apoptosis
corelates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia.
Br J Haematol. 2001;113(2):391-399. 2.815
46 Meloni G, Proia A, Guerrisi V, Cordone I, De Cuia R, Fenu S, Mauro FR, Pescarmona E, Reato G, Mandelli F. Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Ann Oncol. 2000 ;11(11):1493-1495. 3.249
45 Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Blood. 2000 1;95(9):2786-2792. 8.977
44 Maloum K, Davi F, Merle-Béral H, Pritsch O, Magnac C, Vuillier F, Dighiero G, Troussard X, Mauro F, Bénichou J. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia.
Blood. 2000 1;96(1):377-379. 8.977
43 Bevan S, Catovsky D, Matutes E, Antunovic P, Auger MJ, Ben-Bassat I, Bell A, Berrebi A, Gaminara EJ, Júnior ME, Mauro FR, Quabeck K, Rassam SM, Reid C, Ribeiro I, Stark P, van Dongen JJ, Wimperis J, Wright S, Marossy A, Yuille MR, Houlston RS. Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia.
Blood. 2000 1;96(12):3982-4. 8.977
42 Meloni G, Proia A, Mauro F, Amaranto P, Capria S, Cimino G, Cordone I, de Fabritiis P, Rapanotti C, Reato G, Vignetti M, Foa R, Mandelli F. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
Haematologica. 2000;85(9):952-960. 2.538
41 Pescarmona E, Pignoloni P, Mauro FR, Cerretti R, Anselmo AP, Mandelli F, Baroni CD. Hodgkin/Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background.
Virchows Arch. 2000;437(2):129-132.
1.928
40 Bottoni U, Mauro FR, Del Giudice M, Innocenzi D, Bonaccorsi P, Mandelli F, Bosman C, Calvieri S. Bollous lesions in chronic lymphocytic leukemia.
Dermatologia Clinica. 2000; 20 (4) X-116 ---
39 De Totero D, Reato G, Mauro F, Cignetti A, Ferrini S, Guarini A, Gobbi M, Grossi CE, Foa R. IL4 production and increased CD30 expression by a unique CD8+T-cell subset in B-cell chronic lymphocytic leukaemia.
Br J Haematol. 1999;104(3):589-599. 3.204
38 Pritsch O, Troussard X, Magnac C, Mauro FR, Davi F, Payelle-Brogard B, Dumas G, Pulik M, Clerget F, Mandelli F, Chiorazzi N, Schroeder HW Jr, Leporrier M, Dighiero G. VH gene usage by family members affected with chronic lymphocyticleukaemia.
Br J Haematol. 1999;107(3):616-624. 3.204
37 Payelle-Brogard B, Magnac C, Mauro FR, Mandelli F, Dighiero G. Analysis of the B-cell receptor B29 (CD79b) gene in familial chronic lymphocytic leukemia.
Blood. 1999 15;94(10):3516-3522. 8.782
36 Bevan S, Catovsky D, Marossy A, Matutes E, Popat S, Antonovic P, Bell A, Berrebi A, Gaminara E, Quabeck K, Ribeiro I, Mauro FR, Stark P, Sykes H, van Dongen J, Wimperis J, Wright S, Yuille MR, Houlston RS. Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia.
Leukemia. 1999;13(10):1497-1500. 3.562
35 Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.
Blood. 1999 15;94(2):448-454. 8.782
34 Zarcone D, De Rossi G, Tenca C, Marroni P, Mauro FR, Cerruti GM, Albi N, Fiorucci S, Velardi A, Grossi CE. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells.
Haematologica. 1998;83(12):1088-1098. 1.876
33 Meloni G, Mauro FR, Proia A, Mandelli F. Chronic lymphocytic leukemia: from palliative therapy to curative intent.
Haematologica. 1998;83(7):660-662. 1.876
32 Sala R, Mauro FR, Bellucci R, De Propris MS, Cordone I, Lisci A, Foà R, de Fabritiis P. Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy.
Eur J Haematol. 1998 ;61(1):14-20. 1.846
31 Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.
Blood. 1998;91(11):4342-9. 8.372
30 Giovannetti A, Quinti I, Rainaldi L, Mauro FR, Oliva A, Pierdominici M, Ricci G, De Rossi G, Cassone A, Aiuti F, Pandolfi F. Proliferative responses to PHA, anti-CD3 and antigens in patients with lymphoproliferative disease of granular lymphocytes. Mannoproteins of Candida albicans induce proliferation and cytotoxicity.
Acta Haematol. 1997;98(2):65-71. 0.784
29 De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S, Grossi CE. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
Leukemia. 1997;11(1):134-41. 3.227

28 De Rossi G, Tenca C, Cerruti G, Favre A, Zarcone D, Tabilio A, Mauro FR, Annino L, Grossi CE. Adhesion molecule expression on B-cells from acute and chronic lymphoid leukemias.
Leuk Lymphoma. 1994;16(1-2):31-36.
27 Mauro FR, De Rossi G, Burgio VL, Caruso R, Giannarelli D, Monarca B, Romani C, Baroni CD, Mandelli F. Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution.
Haematologica. 1994;79(4):334-341.
26 Girmenia C, Mauro FR, Rahimi S. Late listeriosis after fludarabine plus prednisone treatment.
Br J Haematol. 1994;87(2):407-8.
25 Zinzani PL, Levrero MG, Lauria F, Rondelli D, Zaja F, Russo D, Fanin R, De Rossi G, Mauro FR, Bendandi M, Gozzetti A, Dianzani F, Mandelli F, Tura S.
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Haematologica. 1994;79(1):55-60.
24 Ferrari A, Annino L, Perrone MP, Laurenti L, Mauro FR, Girelli G, Mandelli F. HLA typing in hairy cell leukemia (HCL): report of a familial HCL and an association of HCL with chronic lymphocytic leukemia.
J Exp Clin Cancer Res 1993; 12: 163 165.
23 De Rossi G, Zarcone D, Mauro F, Cerruti G, Tenca C, Puccetti A, Mandelli F, Grossi CE. Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets.
Blood. 1993 ;81(10):2679-2687.
22 De Rossi G, Mauro FR, Caruso R, Monarca B, Mandelli F. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
Haematologica. 1993;78(3):167-171.
21 Tosti S, Caruso R, D'Adamo F, Picardi A, Ali Ege M, Girelli G, Mauro FR, Maurillo L, Amadori S. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
Ann Hematol. 1992;65(5):238-239.
20 De Rossi G, Mauro FR, Ialongo P, Coluzzi S, Pizzo F. Monocytopenia and infections in chronic lymphocytic leukemia (CLL).
Eur J Haematol. 1991;46(2):119.
19 De Rossi G, Mauro FR, Pizzo F, Coluzzi S, Luciani M, Mandelli F. Combination of Cytosine-Arabinoside (ARA-C), Cyclophosphamide and Prednisone in the Treatment of B-Chronic Lymphocytic Leukemia in Advanced Stages and Progressive Disease.
Leuk Lymphoma. 1991;5 1:101-103.
18 Arcese W, Mauro FR, Screnci M, Alimena G, Lo Coco F, Iori AP, de Cuia MR, Fazi P, Montefusco E, Mandelli F. Interferon therapy for Ph1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation.
Eur J Cancer. 1991;4: 28-30.
17 Montefusco E, Mauro FR, Lo Coco F, Rondinelli B, Arcese W, Tabilio A, Monarca B, Alimena G, Mandelli F. Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation.
Haematologica. 1990;75(4):391-393.
16 Arcese W, Mauro FR, Alimena G, Lo Coco F, De Cuia MR, Screnci M, Iori AP, Montefusco E, Mandelli F. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation.
Bone Marrow Transplant. 1990;5(5):309-315.
15 Alimena G, De Cuia MR, Mecucci C, Arcese W, Mauro F, Screnci M, Mancini M, Cedrone M, Nanni M, Montefusco E, et al. Cytogenetic follow-up after allogeneic bone-marrow transplantation for Ph1-positive chronic myelogenous leukemia.
Bone Marrow Transplant. 1990;5(2):119-127.
14 Arcese W, Mauro FR, Screnci M, Alimena G, Iori AP, De Cuia MR, Lo Coco F, Montefusco E, Fazi P, Mandelli F. Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation.
Eur J Haematol 1990;52:36-39.
13 Papa G, Mauro FR, Cimino G, Pisani F, Tabilio A, Di Lonardo A. Secondary myelodysplasia/leukemia complex.
Bone Marrow Transplant. 1989;4:141-142.
12 Arcese W, Mauro FR, Screnci M, Iori AP, Papa G, Mandelli F. Alllograft for chronic myeloid leukemia.
Haematologica.1989;74:443-459.
11 Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle D, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.
Br J Haematol. 1988;69(2):239-245.
10 Papa G, Mauro FR, Mandelli F. Therapy-related acute non-lymphoid leukemia.
Haematologica. 1987;72 :130-131.
9 Mandelli F, Cimino G, Mauro FR, Cartoni C, Anselmo AP, Papa G. Prognosis and management of patients affected by multi pre-treated Hodgkin's disease.
Haematologica. 1986;71(3):205-208.
8 Papa G, Arcese W, Mauro FR, Bianchi A, Alimena G, De Felice L, Isacchi G, Pasqualetti D, Malagnino F, Purpura M, et al. Standard conditioning regimen and T-depleted donor bone marrow for transplantation in chronic myeloid leukemia.
Leuk Res. 1986;10(12):1469-1475.
7 Girelli G, Arcese W, Bianchi A, Mauro FR, Malagnino F, Adorno G, Iurlo A, Perrone MP, Papa G. Hemolysis in Rh-negative female recipient after Rh-incompatible bone marrow transplantation for chronic myeloid leukemia.
Haematologica. 1986;71(1):46-49.
6 Papa G, Arcese W, Bianchi A, Mauro FR, Jandolo B, Pompili A, Gessini L, Mandelli F. Cyclosporine-associated bilateral deltoid paralysis after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Haematologica. 1985;70(3):273-274.
5 Arcese W, De Felice L, Lopez M, Mauro FR, Torti F, Vignetti M, Bianchi A, Riguzzi C, Luciani M, Dentamaro T, Papa G. CFU-GM growth and Leu-7 positive cells in SAA patients treated by Combined ISS. Exp Hemat. 1985; 13; (17): 63-68.
4 Papa G, Mauro FR, Anselmo AP, Cimino G, Alimena G, Amadori S, D'Arcangelo E, Giannarelli D, Bosi A, Bellesi G, et al. Acute leukaemia in patients treated for Hodgkin's disease.
Br J Haematol.1984;58(1):43-52.
3 Cimino G, Anselmo AP, Marzullo A, Maurizi Enrici R, Mauro F, Papa G, Mandelli F. MOPP treatment of resistant Hodgkin's disease following ABVD failure.
Tumori. 1983 31;69(5):469-472.
2 Cimino G, Anselmo AP, De Luca AM, Fidani P, Mauro F, Marzullo A, Maurizi Enrici R, Papa G. Bone marrow involvement at onset of Hodgkin's disease.
Tumori. 1983 ;69(1):47-51.
1 Papa G, Mandelli F, Anselmo AP, De Luca AM, Maurizienrici R, Mauro F, Testi AM, Amadori S, Biagini C. Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
Eur J Cancer Clin Oncol. 1982 ;18(9):803-806.

ELENCO NUMERATO DI ALTRE PUBBLICAZIONI E TESTI su LIBRI
1 Guarini A, Mauro FR, Pulsoni A. (2000). Diagnosi e classificazione delle malattie linfoproliferative croniche. Ematologia- Grandangolo. Forum Service Editore s.c.a r.l. pag 1-63
2 Mauro, F., Foa, R., Young patients with chronic lymphocytic leukemia (2004) Chronic Lymphocytic Leukemia. Molecular Genetics, Biology, Diagnosis, and Management, Ed. G.B. Faguet. Humana Press Inc, Totova, New. Jersey ISBN: 9781588290991
3 FR Mauro, M. Gentile, R Foà (2005). Complicazioni infettive nella Leucemia Linfatica Cronica. In: -. La Leucemia Linfatica Cronica. Il Pensiero Scientifico Editore, ISBN: 8849001371
4 R. FOA', GENTILE M, MAURO F. R, DE PROPRIS S, GUARINI A (2005). Leucemia linfatica cronica: il prototipo di una malattia in evoluzione. In: A CURA DI STEFANO MOLICA; La leucemia linfatica cronica. p. 1-10, ROMA: Il Pensiero Scientifico Editore, ISBN: 8849001371
5 Foà R, Del Giudice I, Mauro FR (2010). Terapie innovative. In: Seminari in Ematologia Oncologica. vol. 7 (3), Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche Pavia.
6 FR Mauro, R Foà. Disordini Linfoproliferativi Cronici. (2005) In: Paolo Larizza. Trattato di Medicina Interna. PADOVA: PICCIN, ISBN: 8829917214
7 R. Foà, I. Del Giudice, F.R. Mauro (2008) pag. 171-182. In: Malattie linfoproliferative croniche leucemiche. In: P. Corradini, R. Foà. Manuale di Ematologia, TORINO: Minerva Medica, ISBN: 9788877116185
8 FR Mauro. LEUCEMIA LINFOIDE CRONICA (2019). In: Ematologia di Mandelli. Piccin; ISBN: 978-88-299-2307-6
9 R Foà, I Del Giudice, FR Mauro. In: Malattie linfoproliferative Croniche Leucemiche. Manuale di ematologia CORRADINI P., FOA' R.II edizione (2019) ISBN: 978-88-7711-816-5.
10 Mauro FR. Chronic Lymphocytic Leukemia; Prolymphocytic leukemia (2018In: Hematology. Pathophysiology, Diagnosis and Treatment. Tura S, Cavo M, Zinzani; PL. 2018, Editore EUSCULAPIO; ISBN: 9788893850834